Literature DB >> 7562967

Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency.

P J Hallam1, D S Millar, M Krawczak, V V Kakkar, D N Cooper.   

Abstract

The factor V Leiden variant, responsible for the phenomenon of activated protein C resistance, was found to be less frequent among British (0.06) and Swedish/Danish (0.15) protein C deficiency patients than previously reported in a Dutch study (0.19). In the Swedish population, a significantly increased frequency of the factor V Leiden allele was apparent in protein C deficiency patients as compared to healthy controls. However, this was not found in the British population. Coinheritance of the factor V Leiden variant is therefore unlikely to be the sole determinant of whether a person with protein C deficiency will come to clinical attention. Nevertheless, when patient data were analysed by type of protein C deficiency, it was noted that the frequency of the factor V Leiden variant was 2.8-fold higher in type II patients compared to type I patients. A possible explanation of this disparity is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562967      PMCID: PMC1050547          DOI: 10.1136/jmg.32.7.543

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

1.  Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries.

Authors:  W I Wood; J Gitschier; L A Lasky; R M Lawn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

2.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 3.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

4.  Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.

Authors:  L Shen; B Dahlbäck
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

5.  Anticoagulant protein C pathway defective in majority of thrombophilic patients.

Authors:  J H Griffin; B Evatt; C Wideman; J A Fernández
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

6.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

7.  Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.

Authors:  B P Koeleman; P H Reitsma; C F Allaart; R M Bertina
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

8.  Absence of thrombosis in subjects with heterozygous protein C deficiency.

Authors:  J Miletich; L Sherman; G Broze
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

9.  Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect.

Authors:  C F Allaart; S R Poort; F R Rosendaal; P H Reitsma; R M Bertina; E Briët
Journal:  Lancet       Date:  1993-01-16       Impact factor: 79.321

10.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more
  1 in total

1.  Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients.

Authors:  Abrar Ahmad; Ashfaque A Memon; Jan Sundquist; Peter J Svensson; Bengt Zöller; Kristina Sundquist
Journal:  Gene       Date:  2018-01-09       Impact factor: 3.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.